On the average, one child is diagnosed with cancer in the state each week.
The actual figure is most probably higher because the ‘one per week’ statistics is merely based on records kept by the Sarawak General Hospital (SGH) and the Sarawak Children’s Cancer Society (SCCS).
SCCS vice-president Wong Kok Ping told The Borneo Post at SCCS’s 9th Charity Food Fair here yesterday that on the average, SGH and SCCS records showed a total of more than 50 cases.
“This does not include patients admitted to the private hospitals,” he pointed out.
For the first seven months of this year, 32 children had been diagnosed with various types of cancer. (more…)
No wonder why humans get lung cancer!! Think about this. the sticky tar contains poison and remains in your lungs each time you smoke, and your lungs need much calorie to remove these poisons from your blood! you will live shorter than you think! but think about your family or children’s life!
The hospital said the operation was performed last month on a man in his 60s from Hiroshima Prefecture who was suffering from advanced cancer in the right lung and other parts. It decided to perform the autotransplantation operation because it would not cause rejection or breathing problems from simply removing the lung.
In the operation, a conservation solution for transplantation was injected into the extracted right lung and cancer was removed after a cooling treatment was applied to last for eight hours. The lung was put back into the body after no cancer was confirmed in the lung. The patient recovered his vital capacity up to about 70% and can play golf and do other exercise, according to the hospital……. (more…)
Have you ever wondered why some chain smokers are lucky enough to get away without certain side effects, like lung cancer? While there are other poor souls just might get lung cancer without ever having smoked a single cigarette in their whole lives?
The truth is, smoking will merely increase your chances of getting lung cancer. But that doesn’t mean that smoking cigarettes is a 100 percent guaranteed way of contracting cancer. So what are the factors that trigger lung cancer, in addition to smoking? Or is there no correlation between the two?
Lung cancer is a disease that kills more than a million people annually. It is also the most common form of cancer, that is, more people will die from lung cancer than from any other type of cancer. Statistics tell us that 90 percent of lung cancer cases occur in smokers, that is to say, only 1 in 10 non-smokers are affected by lung cancer. But the real question to ask is: how many smokers are ultimately diagnosed with lung cancer?….. (more…)
There’s a enthusiastic and hairy back to titty cancer. Not the disease itself, which is life-disruptive at its foremost and deathly at its bad. But there are celebratory races with survivors path the completion product, accumulation lifted in crow; press covers conformation celebrities who bang survived the disease; and sound ribbons seemingly everyplace.
Other cancers receive less attention. These cancers may not have a warm and fuzzy side, but we agree that people diagnosed with them deserve our support and kindness.
But one cancer is noteworthy for the lack of empathy and compassion it elicits.
“Lung cancer is the ugly stepsister of cancer,” was how one person described it to me.
When she was diagnosed, most people assumed that she smoked. She didn’t. (Some 10 to 15 percent of people diagnosed with lung cancer are nonsmokers. For reasons not fully understood, lung cancer is more common in nonsmoking women than in nonsmoking men).
Even her friends who knew she didn’t smoke interrogated her to find the cause. There was an underlying sense that if she wasn’t at fault, someone or something else was.
Blame seems to be the unspoken word when lung cancer is discussed.
People with other cancers aren’t blamed. We don’t accuse them or even wonder if they did something to cause their cancers. The cancer just is.
Anyone who has had cancer can tell you how difficult it was to get the diagnosis and then to share that news with family and friends. Imagine how much more difficult it would be if you sensed people thinking — or even saying, “Well, that’s what you get for smoking.”…….. (more…)
A study featured in the July issue of the Journal of Environmental Management investigated and compared two asbestos abatement methods for their operational efficacy and suitability in a healthcare setting.
Asbestos is a naturally occurring mineral that was widely used in thousands of products throughout the 20th century. The mineral is a human carcinogen that is known to cause a range of diseases, including asbestosis, lung cancer and malignant mesothelioma cancer. The latter is often considered the most aggressive form of asbestos-related cancer as mesothelioma patients typically pass away within four to 18 months of diagnosis.
The muse analyzed asbestos abatement of asbestos-contaminated storey tile and mastic in a healthcare background because scrutiny facilities moldiness maintain a unhurt and thriving environment for patients and visitors, as vessel as employees. The two asbestos abatement methods analyzed in this acquisition included (1) practice remotion of level tile and chemical stripping of mastic and (2) the wet rubbing method.
“Healthcare facilities undergoing refurbishment bonk specialised concerns that are exacerbated when the improvement requires asbestos abatement of aged flooring tile and mastic. The actual verbalise of the art for separation of these materials involves recitation remotion of story tile and chemical stripping of mastic. Utilization of these husking chemicals is a headache for facilities whose perception is based on a unhurt, lovesome, and hearty surround. In this acquisition, wet grinding is evaluated as an alternative to chemical stripping of asbestos-containing flooring tile mastic,” expressed researchers……… (more…)
Today, Lung Individual Coalition (LCA) commended Senator Book Kerry (D-MA) for blessing the Lung House Mortality Reduction Act, S.332. This is the original e’er authorizing legislation that establishes a multi-agency, cosmopolitan syllabus targeted at lung crab.
“Thank you Senator Kerry for joining the ontogeny line of national leaders occupation for a author pitying and complete search plan of challenge for lung individual,” said Laurie Fenton Theologizer, LCA Chairperson & CEO. “You are gift wish to a community that has felt so concealed, stigmatized and unheeded for so abundant.”
Lung individual is the major movement of mansion demise nationwide and in Massachusetts. In 2010, it will involve much lives than helping, prostate and port cancers-combined. Of those diagnosed 80% will be either quondam smokers or testament person never preserved at all.
“This is a wonderful utilisation,” said Deborah Morosini, MD, LCA Panel Member and fille of the latish Dana Reeve. “Both Dana and Chris were both eager admirers and accurate friends of Senator Kerry. My sept continues to be so appreciative of the backing he has offered in portion us to fight this disease that has coloured all of our lives so deeply.”
In a latterly free read by the Brigham and Women’s Hospital Connors Midpoint for Women’s Eudaimonia and Gender Assemblage, Philanthropist Medical Affiliate, entitled Out of the Shadows: Women and Lung Individual, researchers noted that this year alone 25,000 women instrument be diagnosed with lung someone who never smoked a day in their lives….. (more…)
Cancer Survivors Pack The Track at The American Cancer Society’s Relay For Life of Clark:
177 cancer survivors lead the way during the “Survivor Celebration Lap” at the American Cancer Society’s Relay For Life of Clark on Friday, June 11, 2010. Two-thousand participants including 113 teams raised over $204,000 in donations in the fight against cancer. One-Hundred participants enrolled at the event for “CPS-3”, a nationwide Cancer Prevention Study which will help researchers find new ways to prevent cancer.
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study showing microRNA expression differentiates between primary lung tumors and metastases to the lung. The study, entitled, “MicroRNA expression differentiates between primary lung tumors and metastases to the lung,” was published in the online edition of Pathology Research and Practice on April 28, 2010. The article is available at the following URL: see here.
Differentiating whether a pulmonary neoplasm is primary or metastatic can be challenging for surgical pathologists, and is an important distinction for clinicians in determining the proper treatment protocols. Current biomarkers do not always aid lung tumor classification. The study’s authors identified a set of microRNAs that is expressed differentially between these two groups using microRNA microarray data generated from 76 formalin-fixed, paraffin-embedded (FFPE) samples of either primary lung cancer or metastatic tumors to the lung.
According to the study, “The tissue-associated expression of microRNA likely explains the remarkable finding that many tumors can be classified based solely on their microRNA expression signature. Here we show that microRNAs can serve as biomarkers for lung tumor classification.”
“These data offer further evidence of the flexibility and potential wide range of clinical applicability of our microRNA technology. The growing body of literature, as well as our commercial line of miRview™ tests, continue to demonstrate that microRNAs are highly reliable and powerful biomarkers for a wide range of indications,” noted Kenneth A. Berlin, President and CEO of Rosetta Genomics. … (more…)
Biopsy-based study tilts field toward personalized treatment, more efficient clinical trials
The first lung cancer clinical trial to guide targeted therapies to patients based on molecular signatures in tumor biopsies is a step toward personalized care and more effective, efficient clinical trials for new drugs, study leaders reported today during the American Association for Cancer Research 101st Annual Meeting 2010.
Researchers at The University of Texas M. D. Anderson Cancer Center presented the results of the study that used an innovative statistical model to match four drugs to specific molecular signatures, or biomarkers, in the tumors of 255 stage IV non-small cell lung cancer patients who had received between one and nine previous treatments.
“New drugs that target molecular pathways help a small percentage of lung cancer patients, but right now there’s no way to determine who those patients are before treatment,” said Edward Kim, M.D., associate professor in M. D. Anderson’s Department of Thoracic/Head and Neck Medical Oncology and principal investigator on the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) clinical trials.
“BATTLE evaluated tumor biomarkers in hopes that we can treat lung cancer, which kills more people than any other type of cancer, like we treat breast or colon cancer, using validated biomarkers to guide treatment and improve survival,” Kim said. The National Cancer Institute estimates that 219,440 new cases of lung cancer were diagnosed in 2009 and 159,390 people died from the disease.
Kim said BATTLE also points the way to more precise clinical trials that will require smaller numbers of patients to test a targeted therapy rather than large trials open to all-comers. “Lung cancer research has been plagued by large, Phase III clinical trials that showed minor effects or even failed to enroll enough patients to finish,” Kim said.
“Two lung cancer tumors might appear identical under a microscope and have the same staging, but they behave differently,” said Waun Ki Hong, M.D., head of M.D. Anderson’s Division of Cancer Medicine and principal investigator on the BATTLE grant from the U.S. Department of Defense. “The name of the game now is to treat based on the molecular defects in the tumor.”
The Phase II clinical trial found evidence that each of the four drugs targets specific molecular signatures better than the other three. The drugs used in the trial were erlotinib (Tarceva-), sorafenib (Nexavar-), vandetanib (Zactima-) and erlotinib with bexarotene (Targretin-). Each drug is designed to target specific molecular pathways; currently, none has a validated biomarker to guide its use…. (more…)
